J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
Takeo KosakaNozomi HayakawaMasashi NakayamaMasahiro UnoHiroomi NakatsuChiyoe KitagawaHideaki MiyakeTakeshi YamadaKazutoshi FujitaHideaki ShimoyamaKiyoaki NishiharaMizuki KobayashiMotonobu NakamuraKiyohide FujimotoTakeshi SanoNaotaka NishiyamaTakayuki ItoMasahiro KajitaTakashi KobayashiHiroshi KitamuraPublished in: International journal of urology : official journal of the Japanese Urological Association (2024)
Findings from J-AVENUE show the effectiveness of avelumab first-line maintenance in patients with advanced urothelial carcinoma in Japan in clinical practice, with similar progression-free survival to JAVELIN Bladder 100 and previous real-world studies, supporting its use as a standard of care.